JEAN-PIERRE RAUFMAN, M.D.
To the editor: I would like to bring to your attention an error in sulfasalazine dosing in the article by Peppercorn (1). On page 384, the article reads "These authors now advocate discontinuance of sulfasalazine treatments for 1 to 2 weeks in patients who have nausea, vomiting, abdominal pain, headache, reticulocytosis, and mild rash; treatment then can be restarted at a dose of 0.125 to 0.25 g/d for 1 week, with a gradual increase by 0.125 g/wk to a maintenance dose of 2 g/wk." The doses given as g/wk should both read g/d with substitution of the word weekly for
RAUFMAN J. Correction: Sulfasalazine Dose. Ann Intern Med. ;102:139. doi: 10.7326/0003-4819-102-1-139_3
Download citation file:
Published: Ann Intern Med. 1985;102(1):139.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use